Background: Administration of trastuzumab, a fully humanized monoclonal antibody targeted to the human epidermal growth factor receptor 2 (HER2, p185), has improved outcomes for patients with HER2-positive gastric cancer (GC), but some relevant issues remain to be investigated and will emerge with new anti-GC drugs. Gastrin is a major gastrointestinal hormone proven to have an inhibitory effect on GC in vitro and in vivo.
Aim: To explore the sympathetic role of trastuzumab and gastrin on inhibition of GC.
Methods: The HER2-positive and HER2-negative GC cell lines were treated with trastuzumab, gastrin, or their combination in vitro and in xenograft model. The synergistical role of trastuzumab and gastrin and related mechanisms were investigated.
Results: We found the synergistic inhibitory effects of trastuzumab and gastrin on HER2-negative GC cells through the gastrin/cholecystokinin B receptor (CCKBR) pathway. Trastuzumab upregulated CCKBR protein levels but could not initiate its signal transduction, whereas gastrin increased the levels and activation of CCKBR. Molecular experiments indicated that trastuzumab and gastrin co-treatment synergistically enhanced the stability of CCKBR. Moreover, their combined treatment synergistically arrested GC cells at G0/G1 phase, down-regulated levels of GC-related proteins, including anion exchanger 1 (AE1), cyclin D1, β-catenin, and cytoplasmic p16, and promoted nuclear translocation of p16. In addition, combination treatment upregulated AE2 levels, which are reduced in GC tissues. The in vivo synergistic anti-GC effect of combined treatment was confirmed in xenograft experiments.
Conclusions: Trastuzumab plus gastrin inhibit growth of Her2-negative GC by targeting cytoplasmic AE1 and p16.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10620-015-3793-7 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Role of Theragnostics in Breast Cancer: A Systematic Review of the Last 12 Years.
Curr Med Imaging
May 2023
Department of Medical Science, Division of Nuclear Medicine, University of Turin, Turin, Italy.
Background: Breast cancer is the most common malignancy in women, with high morbidity and mortality. Molecular alterations in breast cancer involve the expression or upregulation of various molecular targets that can be used for diagnostic nuclear medicine imaging and radiopharmaceutical treatment. Theragnostics is based on the binding of radionuclides to molecular targets.
View Article and Find Full Text PDFMolecular Imaging in Breast Cancer.
Nucl Med Mol Imaging
October 2019
Institute of Pathophysiology and Nuclear Medicine Academician Isak S.Tadzer, Faculty of Medicine, University Ss. Cyril and Methodius in Skopje, Mother Theresa 17, 1000 Skopje, North Macedonia.
Breast cancer (BC) is the most common cancer among females with more than 2 million new cases diagnosed worldwide in 2018. Although the prognosis in the majority of cases in the early stages combined with appropriate treatment is positive, there are still about 30% of patients who will develop locoregional diseases and distant metastases. Molecular imaging is very important in the diagnosis, staging, follow-up, and radiotherapy planning.
View Article and Find Full Text PDFTrastuzumab cotreatment improves survival of mice with PC-3 prostate cancer xenografts treated with the GRPR antagonist Lu-DOTAGA-PEG -RM26.
Int J Cancer
December 2019
Department of Medicinal Chemistry, Uppsala University, Uppsala, Sweden.
Gastrin-releasing peptide receptors (GRPRs) are overexpressed in prostate cancer and are suitable for targeted radionuclide therapy (TRT). We optimized the bombesin-derived GRPR-antagonist PEG -RM26 for labeling with Lu and further determined the effect of treatment with Lu-labeled peptide alone or in combination with the anti-HER2 antibody trastuzumab in a murine model. The PEG -RM26 analog was coupled to NOTA, NODAGA, DOTA and DOTAGA chelators.
View Article and Find Full Text PDFTrastuzumab Inhibits Growth of HER2-Negative Gastric Cancer Cells Through Gastrin-Initialized CCKBR Signaling.
Dig Dis Sci
December 2015
Pathology Center, Shanghai First People's Hospital/Faculty of Basic Medicine, Shanghai Jiao Tong University School of Medicine, Number 280, South Chong-Qing Road, Shanghai, 200025, China.
Background: Administration of trastuzumab, a fully humanized monoclonal antibody targeted to the human epidermal growth factor receptor 2 (HER2, p185), has improved outcomes for patients with HER2-positive gastric cancer (GC), but some relevant issues remain to be investigated and will emerge with new anti-GC drugs. Gastrin is a major gastrointestinal hormone proven to have an inhibitory effect on GC in vitro and in vivo.
Aim: To explore the sympathetic role of trastuzumab and gastrin on inhibition of GC.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!